Latest close: below its 200-day averageSep 8, 2026what changed →
Is the price fair?
What BEAM's price assumes
Beam Therapeutics Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 15.0× revenue.
15.0
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 2.11
Price / book · as of 2026-Q1
- EV / sales
- 13.9
EV / sales
Details›
- Price / book2026-Q1
- 2.11
- EV / EBIToperating margin −242%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 13.9
- Market capitalisation
- $3.49B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.